Acorda gains on data in stroke patients
Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.98 (13%) to $35.50 on Monday after reporting data from a Phase II trial evaluating the company's dalfampridine to treat chronic neurological deficits following ischemic stroke. Twice-daily oral dalfampridine extended release (ER) tablets for 14 days significantly improved walking speed from baseline as measured by the Timed 25 Foot Walk (T25FW) test vs. placebo (p<0.05). The double-blind, crossover, U.S. trial enrolled 83 patients who had experienced an ischemic stroke at least six months prior to enrollment and who had chronic motor deficits. Acorda said it plans to discuss the development program of dalfampridine-ER to treat post-stroke deficits with FDA, but declined to disclose details. ...